Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive antibody could boost stem cell transplant success in tough leukemias

NCT ID NCT03128034

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing a new approach for people with high-risk acute leukemias or myelodysplastic syndrome. Before a donor stem cell transplant, patients receive a radioactive antibody (211At-BC8-B10) designed to target and kill cancer cells while sparing healthy tissue. The goal is to find the safest dose and see if this improves transplant outcomes. About 75 participants will be enrolled in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

radioactive antibody (211At-BC8-B10)

What this could lead to

If it works, this could provide a more targeted way to destroy leukemia cells before a stem cell transplant, potentially reducing relapse and improving survival for patients with hard-to-treat blood cancers.

What could go wrong

This is an early-phase trial (Phase 1/2) with only 75 participants, so the benefits are unproven. The radioactive antibody may cause severe side effects, and the transplant itself carries risks like graft-versus-host disease or infection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute lymphoblastic leukemia acute myeloid leukemia acute myeloid leukemia with multilineage dysplasia chronic myelomonocytic leukemia mixed phenotype acute leukemia myelodysplastic syndrome with excess blasts Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE MYELOID LEUKEMIA ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME CHRONIC MYELOMONOCYTIC LEUKEMIA MIXED PHENOTYPE ACUTE LEUKEMIA MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA RECURRENT ACUTE MYELOID LEUKEMIA RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA REFRACTORY ACUTE MYELOID LEUKEMIA REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact